| Document |
Document Title |
|
WO/2012/091261A1 |
The present invention relates to a method for manufacturing solid powder derived from carbazic acid, which involves inducing a reaction of a liquid hydrazine derivative with carbon dioxide at a high pressure of about 0.5 MPa to about 100...
|
|
WO/2012/032257A1 |
The invention relates to novel guanidine derivatives in the cinnamic series of general formula (I). The invention also relates to the method for preparing said guanidine derivatives and also synthesis intermediates. Finally, the inventio...
|
|
WO/2012/025038A1 |
Disclosed is a continuous manufacturing method for the synthesis of hydazo dicarbonamide. The method comprises: (1) adding hydrazine hydrate and a urea solution into an oscillating flow tube crystallizer via the mid-lower section thereof...
|
|
WO/2011/138410A1 |
The present invention relates to flame retardant polymer compositions which comprise aminoguanidine phenylphosphinates and mixtures with additional flame retardants. The compositions are especially useful for the manufacture of flame ret...
|
|
WO/2011/026193A1 |
The present invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt or solvate or thereof. In particular, the present invention relates to a method treating diseases involving cell proliferation, migr...
|
|
WO/2010/117064A1 |
A compound having a hetero ring skeleton represented by general formula (I), a tautomer of the compound, or a salt of the compound or the tautomer, which is useful as a catalyst for asymmetric synthesis. [In the formula, R1 and R2 indepe...
|
|
WO/2010/114536A1 |
Disclosed herein are acylhydrazone and semicarbazones derivatives of aldehydes and ketones that may act to attract plant pathogenic zoospores and methods of using these compounds. These compounds include the compound according to Formula...
|
|
WO/2010/096383A1 |
An apparatus for providing a reactant comprises a reactant space and a reservoir space. The reactant space comprises a chemical complex capable of evolving the reactant when heated. The reservoir space, in turn, is in gas communication w...
|
|
WO/2010/084292A1 |
The present invention relates to azapeptide or azapeptidomimetic compounds of formula (I): where R1, R2, R3, X1, X2, X2, X4 and Y are as defined in claim 1, to the pharmaceutical compositions containing said compounds and to such compoun...
|
|
WO/2010/060231A1 |
The present invention provides a kind of nitroguanidine compounds, its preparation method and uses. The structure of the compound is as follows of formular I, in which R1 is saturated or unsaturated C1-10 aliphatic alkyl, benzyl or subst...
|
|
WO/2010/047400A1 |
A compound represented by formula (1). (In the formula, Ar represents an optionally substituted aromatic hydrocarbon group having 6-20 carbon atoms; Ar' represents an optionally substituted aromatic hydrocarbon group having 6-20 carbon a...
|
|
WO/2010/000634A1 |
The present invention relates to a process for the isomerization of the Z-isomer I-Z of a semicarbazone compound of the general formula (I) into its E-isomer I-E wherein the variables in formula (I) have the meanings as defined in the de...
|
|
WO/2009/148869A1 |
Ligand functionalized substrates, methods of making ligand functionalized substrates, and methods of using functionalized substrates are disclosed.
|
|
WO/2009/145360A1 |
The present invention provides a novel benzene derivative or thiophene derivative useful as a VAP-1 inhibitor, or a medicament for the prophylaxis or treatment of a VAP-1 associated disease and the like, namely, a compound represented by...
|
|
WO/2009/137444A2 |
The present invention provides compound(s) selected from the group of compounds represented by structural Formula (I): wherein X, Y and R1 are described herein, use of such compounds as anaerobic cure accelerators, and compositions inclu...
|
|
WO/2009/111037A2 |
The disclosures herein provide lipoic acid salts, as well as polymorphs, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administrat...
|
|
WO/2009/075890A2 |
The present invention provides novel method of synthesis of compounds which inhibit the activity of Hsp90. In one embodiment, the present invention is a method of synthesis of a compound of formula (IA) cyclization of a compound of formu...
|
|
WO/2009/049837A1 |
The invention relates to a process for preparing 8-aryloctanoyl derivatives, in particular chiral 8-hydrazino-8-aryloctanoyl amides, and also novel intermediates which are used in the process for preparing the octanoyl derivatives mentio...
|
|
WO/2008/098751A1 |
The present invention provides new compounds displaying antiglutamatergic properties. It also provides the use of such compounds for the treatment and/or prophylaxis of conditions and diseases linked to abnormalities in glutamatergic tra...
|
|
WO/2008/095903A1 |
The present invention refers to a new addition salt of N-amino-N - pentylguanidine, particularly to the oxalate addition salt of N-amino-N - pentylguanidine.The process for preparing saidoxalate addition salt comprises the steps of:a) re...
|
|
WO/2008/093702A1 |
Disclosed are: a bis(2-alkoxyethyl) azodicarboxylate ester compound which can be used in combination with a phosphorus compound in a Mitsunobu reaction for achieving a dehydration/condensation reaction, is useful as an oxidizing agent or...
|
|
WO/2008/071980A1 |
There are described compounds of general formula (I) and isomeric forms thereof wherein n is 0,1,2 or 3, saturated or unsaturated; most preferably at least one of R1 to R5 represents halogen; at least one of R1, R2, R3, R4 and R5 is sele...
|
|
WO/2008/019798A1 |
A novel process for the preparation of lamotrigine and its intermediates is devised.
|
|
WO/2007/122847A1 |
A reagent for organic syntheses with which a chemical reaction can be conducted in a liquid phase and unnecessary compound(s) can be easily separated at low cost from the liquid phase after completion of the reaction. The reagent for org...
|
|
WO/2007/118681A1 |
The invention relates to a method for producing 8-aryl-octanoyl derivatives, especially chiral 8-aryl-octanoyl amides, as well as novel intermediate products that are used in said method for producing the inventive octanoyl derivatives, ...
|
|
WO/2007/119042A2 |
The present invention relates to a process for the treatment of a product stream, more specifically of a product stream from an autothermal cracking process, said product stream comprising one or more olefins, hydrogen, carbon monoxide, ...
|
|
WO/2007/056469A2 |
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.
|
|
WO/2007/015999A2 |
The present application relates to a process for the synthesis of the compound of formula 1. The compound of formula I is a glucagon receptor antagonist and is useful for treating, preventing or delaying the onset of type 2 diabetes mell...
|
|
WO/2007/000250A1 |
The invention relates to a method for producing aryl or heteroaryl amines, ethers or thioethers (III) by cross-coupling primary or secondary amines, alcohols or thioalcohols (II) with substituted aryl or heteroaryl compounds (I) in the p...
|
|
WO/2006/093124A1 |
It is intended to provide a novel free radical scavenger for removing active oxygen which is causative for various diseases in vivo and results in degradation and color fade-out in commercial products. A free radical scavenger which cont...
|
|
WO/2006/083266A1 |
In accordance with the present invention, compounds having formula (I), where the variables are as identified in the claims, that inhibit Type III protein secretion have been identified, and methods for their use provided. In one aspect ...
|
|
WO/2006/048526A2 |
The invention relates to a rapid-action depilatory composition, comprising at least one bisulphite and/or sulphite compound selected from the bisulphites or sulphites of potassium, calcium, lithium barium or strontium, the alkaline salts...
|
|
WO/2006/032893A2 |
The present invention provides a compound of the formula: (IIa); having a reactive functional group M, capable of reacting with a biopolymer, BP, having at least one group capable of reacting with M to form a covalent linkage, to provide...
|
|
WO/2005/107762A2 |
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.
|
|
WO/2005/090293A1 |
The invention relates to a method for producing semicarbazone compounds of formula (I) wherein R1 and R2 independently represent hydrogen, halogen, CN, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl or C1-C4 haloalkoxy, and R3 represents C1-...
|
|
WO/2005/085216A1 |
An isoxazoline-substituted benzamide compound of the general formula: (1) [wherein each of A1, A2 and A3 independently represents a carbon atom or nitrogen atom; G a benzene ring, etc.; W an oxygen atom or sulfur atom; X a halogen atom, ...
|
|
WO/2005/073216A2 |
Compounds of the formula (F) where the variables are as defined in the specification inhibit the NS3 protease of flavivirus sych as hepatitis C virus (HCV). The compounds comprise a novel linkage between a heterocyclic P2 unit and those ...
|
|
WO/2005/073195A2 |
Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocycli...
|
|
WO/2005/047235A1 |
The present invention relates to the isomerisation of the Z-isomer I-Z of semicarbazone compounds of the general formula (I) into its E-isomer I-E, where the variables in formula (I) have meanings given in claim 1.
|
|
WO/2005/031000A2 |
The invention described below relates to the discovery of the neuropeptide FF receptor subtype that mediates acute nociception and chronic neuropathic pain, compounds that selectively interact with this receptor subtype and methods for t...
|
|
WO/2004/111086A2 |
The invention relates to peptide analogues or parent proteins comprising at least one type of aminoacyl aza-$g(b)3 residue and to the use thereof for pharmaceutical compositions or for diagnosis of pathologies involving said peptides or ...
|
|
WO/2004/106289A1 |
A monoacyl semicarbazide of the general formula (I): (I), or a pharmaceutically acceptable salt or ester thereof, is capable of selectively inhibiting dipeptidyl-peptidase I (DPP-I), also known as cathepsin C. A compound of the invention...
|
|
WO/2004/101752A2 |
Novel acyl urea, carbamate, thiocarbamate and related compounds are provided which are effective in inhibiting the cytokine-mediated inflammatory response in cultured cells, in ameliorating bone destruction in an animal model of arthriti...
|
|
WO/2004/078924A2 |
The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding...
|
|
WO/2004/052841A1 |
Prodrugs of carbidopa, derivatives of carbidopa prodrugs, methods of making prodrugs of carbidopa and derivatives thereof, methods of using prodrugs of carbidopa and derivatives thereof, and compositions of prodrugs of carbidopa and deri...
|
|
WO/2004/050689A2 |
Provided are peptides comprising at least one azaamino acid and having β-sheet breaking ability, useful in the treatment and prevention of diseases such as alzheimer’s disease, Dementia Pugilistica (including head trauma), Hereditary ...
|
|
WO/2004/039767A1 |
The invention discloses a method for preparing the intermediate 2-(2,3-dichlorophenyl)-2-(aminoguanidine) acetonitrile of formula (II), which comprises the reaction of 2,3-dichlorobenzoyl cyanide with aminoguanidine bicarbonate in non-aq...
|
|
WO2002083842A9 |
The invention features compounds that inhibit section of a protein encoded by an ARE-mRNA or that modulate regulation of an ARE-mRNA. These compounds are useful for the treatment or prevention of conditions involving proteins encoded by ...
|
|
WO/2004/033417A2 |
The invention relates to the inhibition of S-adenosyl methionine decarboxylase for the prevention and/or the treatment of a herpes simplex virus infection.
|
|
WO/2004/028538A1 |
Small organic molecules capable of effecting a 'pharmacological trabeculocanalotomy' in an eye by means of reducing juxtacanalicular meshwork as a barrier to outflow of aqueous. The small organic molecules increase Gelatinase A activity ...
|
